The effect of evening primrose oil on fatigue and quality of life in patients with multiple sclerosis

Figures & data

Table 1 Patient’s clinical and demographic characteristics

Study group	Control group		Experimental group
Number	26 patients		26 patients
Gender	Female	Male	Female	Male
	18	8	20	6
Age	20–55 years old		20–55 years old
Disease duration	1–5 years		1–5 years
MS type	RRMS		RRMS
Disease modifying treatment	Interferon β 1a (cinovex) or glatiramer		Interferon β 1a (cinovex) or glatiramer
EDSS	<6 and more patients were 1–3		<6 and more patients were 1–3
Depression score	0–7 normal		0–7 normal

Note: Depression scores in patients ranging from 0 to 7 were considered in the normal range and were included in the study, but those with a depression score over 7 were considered depressed and were not included in the study from the beginning.

Abbreviations: RRMS, relapsing/remitting multiple sclerosis; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis.

Figure 1 Comparison of vitality before treatment and 3 months after treatment in the 2 groups, control (placebo) and experimental.

Figure 2 Comparison of scores on the pain scale before treatment and 3 months after treatment in the 2 groups, control (placebo) and experimental.

Figure 3 Comparison of cognitive function before treatment and 3 months after treatment in both groups, control (placebo) and experimental.

Figure 4 Comparison of overall life satisfaction before treatment and 3 months after treatment in both groups, control (placebo) and experimental.

Figure 5 Comparison of fatigue scale scores before treatment and 3 months after treatment in both groups, control (placebo) and experimental.